No Data
No Data
Kineta | 10-Q: Quarterly report
Kineta Enters Into $5 Million Agreement With TuHURA Biosciences for Vista Blocking Immunotherapy; Shares Rise
Express News | Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
Express News | Kintara Therapeutics Inc - Under Terms of Agreement, Tuhura Will Pay Kineta $5.0 Mln
Express News | Kineta Inc: Kineta Will Receive a $5 Mln Nonrefundable Payment From Tuhura
No Data